IL291499B1 - Aza-quinoline compounds and uses thereof - Google Patents
Aza-quinoline compounds and uses thereofInfo
- Publication number
- IL291499B1 IL291499B1 IL291499A IL29149922A IL291499B1 IL 291499 B1 IL291499 B1 IL 291499B1 IL 291499 A IL291499 A IL 291499A IL 29149922 A IL29149922 A IL 29149922A IL 291499 B1 IL291499 B1 IL 291499B1
- Authority
- IL
- Israel
- Prior art keywords
- amino
- methyl
- cyclohexyl
- trans
- naphthyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (29)
1. 291499/ CLAIMS 1. A compound of Formula (I): Formula (I), or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof, wherein: Y is N or CR; R, R and R are independently H, halogen or -C1-C 4 alkyl; R is -CN, -C1-C 6 alkyl, -C1-C 4 alkylene-hydroxy, -C1-C 6 alkyl substituted with -N(C1-C 4 alkyl)2, -C1-C 4 alkoxy, -C2-C 4 alkoxy substituted with 1-2 hydroxyl or cyano, -NH2, -NRC(=O)R, -C(=O)NH2, -(CH2)nR, -R, -NHC(=O)R, -NRC(=O)OR, -C(=O)NRR, -(CH2)nC(=O)NRR, -(CH2)nNRR, -(CH2)nC(=O)NRR, -C(=O)NRR, -CRRC(=O)NRR, -OCRRR, -(CH2)nC(=O)R, -C(=O)R, -CRRC(=O)R, -(CH2)nNRC(=O)R, -(CH2)nNR(CH2)2C(=O)R, -NRC(=O)(CH2)2C(=O)R, -(CH2)nOR, -(CH2)nNRC(=O)OCH2R, -NRC(=O)OCH2R, -(CH2)nNR(CH2)nR, , -C1-C alkyl substituted with one Ra, -C1-C 4 alkoxy substituted with one Rb, or a 5- to 6- membered heteroaryl having 1 to 4 ring members independently selected from O, S, N and -NRc, wherein Ra is -C1-C 4 alkoxy and Rb is -C1-C 4 alkoxy; R5a, R5b, R5c, R5d and Rc are independently H or -C1-C 4 alkyl; R, R, R and R are independently H, halogen or -C1-C 4 alkyl; R is H, halogen, -C1-C 4 alkyl, -C1-C 4 alkoxy, -C1-C 4 haloalkoxy or -NH(C1-C 4 alkyl); R is H, -C1-C 4 alkyl, -SO2(C1-C4 alkyl), -C1-C 4 alkylene-hydroxy, -C1-C 4 alkylene-cyano or -C1-C 4 alkyl substituted with -C1-C 4 alkoxy; R is H or -C1-C 4 alkyl; R is H, halogen, -CN, -OH, -C1-C 4 alkyl or –C1-C 4 alkylene-hydroxy; Ris H, halogen or -C1-C 4 alkyl; 291499/ R is , -C3-C6cycloalkyl, or a 4- to 6-membered heterocycoalkyl having 1-2 ring members independently selected from O, S, S(=O) 2, N and -NR, wherein said -C3-C6cycloalkyl and 4- to 6- membered heterocycloalkyl are independently unsubstituted or substituted with 1-2 substituents selected from -OH, -C1-C 4 alkyl, -C1-C 4 alkylene-hydroxy, -C1-C 4 alkoxy and -N(C1-C 4 alkyl)2; R, if present, is halogen, -CN, -OH, -C1-C 4 alkyl or -C1-C 4 alkylene-hydroxy; m is 0, 1 or 2; each n is independently selected from 1 and 2; and provided that the compound of Formula (I) is not (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(4-methylpiperazin-1-yl)methanone.
2. The compound of claim 1, wherein said compound is of Formula (I-4): Formula (I-4), or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 or claim 2, wherein: R is -CN, -NH2, -C(=O)NH2, -NHC(=O)R, -NRC(=O)OR, -C(=O)NRR, -(CH2)nC(=O)NRR, -(CH2)nNRR, -(CH2)nC(=O)NRR, -C(=O)NRR, -CRRC(=O)NRR, -OCRRR, -(CH2)nR, -NRC(=O)(CH2)2C(=O)R, -(CH2)nNRC(=O)OCH2R, -NRC(=O)OCH2R, -(CH2)nNR(CH2)nR, -(CH2)nC(=O)R, -CRRC(=O)R, -(CH2)nNRC(=O)R, -NRC(=O)R, -(CH2)nNR(CH2)2C(=O)R, -(CH2)nOR, , , -C1-C 6 alkyl substituted with one Ra, -C1-C 4 alkoxy substituted with one Rb, or a 5- to 6- membered heteroaryl having 1 to 4 heteroatoms independently selected from N and -NRc wherein Rc is H or -C1-C 4 alkyl; 291499/ Ra is -C1-C 4 alkoxy; and Rb is -C1-C 4 alkoxy.
4. The compound of claim 1 or claim 2, wherein: R is -CN, -NH2, -C(=O)NH2, -NHC(=O)R, -NRC(=O)OR, -C(=O)NRR, - CH2C(=O)NRR, triazolyl, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , -C1-C 6 alkyl substituted with one Ra, or -C1-C 4 alkoxy substituted with one Rb; Ra is -C1-C 4 alkoxy; and Rb is -C1-C 4 alkoxy.
5. The compound of claim 1 or claim 2, wherein R is -CH2C(=O)NRR, , , , , , , 291499/ , , , , or -C1-C 6 alkyl substituted with one Ra; and Ra is -C1-C 4 alkoxy.
6. The compound of claim 1 or claim 2, wherein R is , , , , , or ; and Ra is -C1-C 4 alkoxy.
7. The compound of any one of claims 1-6, wherein R is -CN, -NH2, -C(=O)NH2, triazolyl, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , 291499/ , , , , , , , , , , , , , , , , , , , , , , or .
8. The compound of any one of claims 1-6, wherein R is , , , , , , , , , , , , , , , , , , , , , , , , or . 291499/
9. The compound of claim 1, wherein said compound is of Formula (II): Formula (II), or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof; wherein: Y is CH or N; R, R, R5a, R5b, R5c and R5d are independently H or -C1-C 4 alkyl; Ris halogen or -C1-C4 alkoxy; R is H, -C1-C 4 alkyl, -C1-C 4 alkylene-hydroxy, -C1-C 4 alkylene-cyano, or -C1-C 4 alkyl substituted with -C1-C 4 alkoxy; R is H, halogen, -OH, -C1-C 4 alkyl or –C1-C 4 alkylene-hydroxy; R is a 4- to 6-membered heterocycloalkyl having 1-2 heteroatoms independently selected from O, S and N; and wherein said 4- to 6-membered heterocycloalkyl is unsubstituted or substituted with 1-2 substituents selected from -OH, -C1-C 4 alkyl, -C1-C 4 alkylene-hydroxy, -C1-C 4 alkoxy and -N(C1-C 4 alkyl)2.
10. The compound of claim 9, wherein said compound is of Formula (II-2): Formula (II-2), or a stereoisomer, enantiomer, enantiomeric mixture or a pharmaceutically acceptable salt thereof.
11. The compound of any one of claims 1-6 and 9-10, wherein R is H, -C1-C 4 alkyl or -C1-C 4 alkyl substituted with one -CN, one -OH or one -OCH3.
12. The compound of any one of claims 1-6 and 9-11, wherein R is H, F, -CN, -OH, -CHor -CH2OH. 291499/
13. The compound of any one of claims 1-6 and 9-12, wherein Ris H, F or -CH3.
14. The compound of any one of claims 9-13, wherein R is azetidinyl or oxetanyl, each of which is unsubstituted or substituted with -OH, -C1-C 4 alkyl or -C1-C 4 alkylene-hydroxy.
15. The compound of claim 14, wherein R is ; R is -C1-C 4 alkyl; and m is 0-1.
16. The compound of claim 14, wherein R is .
17. The compound of claim 1, wherein said compound is selected from: N-(((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)pyrimidine-2,5-diamine; N-(2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)azetidine-3-carboxamide; N-(2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-methylazetidine-3-carboxamide; 2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carbonitrile; 2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carboxamide; N-(2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)acetamide; 2-hydroxy-N-(2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)acetamide; (2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(piperazin-1-yl)methanone; N-(2-hydroxypropyl)-2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carboxamide; 291499/ (2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(morpholino)methanone; (2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(4-methylpiperazin-1-yl)methanone; N-((1,4-trans)-4-(((5-(1H-1,2,4-triazol-5-yl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-8-methoxy-1,7-naphthyridin-2-amine; 2-(2-((((1,4-trans)-4-((8-methoxy-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)acetamide; N-(((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)pyrimidine-2,5-diamine; methyl (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)carbamate; 2-methoxyethyl (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)carbamate; 2-hydroxyethyl (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)carbamate; oxetan-3-ylmethyl (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)carbamate; N-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-2-hydroxyacetamide; N-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-4-morpholino-4-oxobutanamide; 2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carbonitrile; (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(morpholino)methanone; (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(piperazin-1-yl)methanone; 2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)-N-(oxetan-3-yl)pyrimidine-5-carboxamide; 8-chloro-N-((1,4-trans)-4-(((5-((4-(methylsulfonyl)piperazin-1-yl)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 8-chloro-N-((1,4-trans)-4-(((5-((oxetan-3-ylamino)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 291499/ 8-chloro-N-((1,4-trans)-4-(((5-(((3-methyloxetan-3-yl)amino)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 1-((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)methyl)azetidin-3-ol; 4-((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)methyl)thiomorpholine 1,1-dioxide; 8-chloro-N-((1,4-trans)-4-(((5-(((oxetan-3-ylmethyl)amino)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 8-chloro-N-((1,4-trans)-4-(((5-(((3-methoxycyclobutyl)amino)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 3-(((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)methyl)amino)cyclobutan-1-ol; (2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1,3-dioxan-5-yl)methanol; 8-chloro-N-((1,4-trans)-4-(((5-((oxetan-3-yloxy)methyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)acetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-methyl-N-(oxetan-3-yl)acetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)ethan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-(dimethylamino)pyrrolidin-1-yl)ethan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(4-(2-hydroxyethyl)piperazin-1-yl)ethan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(piperazin-1-yl)ethan-1-one; 2-(6-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyridin-3-yl)-N-(oxetan-3-yl)acetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(4-methylpiperazin-1-yl)ethan-1-one; 291499/ 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-cyclobutylacetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(4-(2-methoxyethyl)piperazin-1-yl)ethan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)ethan-1-ol; 8-chloro-N-((1,4-trans)-4-(((5-(2-((3-methyloxetan-3-yl)amino)ethyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 8-chloro-N-((1,4-trans)-4-(((5-(2-(oxetan-3-ylamino)ethyl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-1,7-naphthyridin-2-amine; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(2-cyanoethyl)-N-(oxetan-3-yl)acetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(2-cyanoethyl)-N-ethylacetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(2-hydroxyethyl)-N-(oxetan-3-yl)acetamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide; (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-methyl-N-(oxetan-3-yl)propanamide; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-methyl-N-(oxetan-3-yl)propanamide; (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-methyl-N-(oxetan-3-yl)propanamide; N-((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)methyl)azetidine-2-carboxamide; 291499/ N-((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)methyl)oxetane-3-carboxamide; 2-((((1,4-trans)-4-((8-(methylamino)-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carbonitrile; 2-((((1,4-trans)-4-((8-(methylamino)-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidine-5-carboxamide; N-((1,4-trans)-4-(((5-aminopyrimidin-2-yl)amino)methyl)cyclohexyl)-N-methyl-1,7-naphthyridine-2,8-diamine; N-(2-((((1,4-trans)-4-((8-(methylamino)-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)acetamide; 3-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)oxazolidin-2-one; methyl (2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)(methyl)carbamate; N-(((1,4-trans)-4-((8-(difluoromethoxy)-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)pyrimidine-2,5-diamine; N-((1,4-trans)-4-(((5-(4H-1,2,4-triazol-3-yl)pyrimidin-2-yl)amino)methyl)cyclohexyl)-8-chloro-1,7-naphthyridin-2-amine; 2-((2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)oxy)propan-1-ol; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)propan-1-one; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)propan-1-one; (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)propan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-3-hydroxy-N-(oxetan-3-yl)propanamide; (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-3-hydroxy-N-(oxetan-3-yl)propanamide; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-3-hydroxy-N-(oxetan-3-yl)propanamide; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-2-hydroxy-N-(oxetan-3-yl)acetamide ; 291499/ (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-2-hydroxy-N-(oxetan-3-yl)acetamide; and 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-2,2-difluoro-N-(oxetan-3-yl)acetamide; or a pharmaceutically acceptable salt thereof.
18. A compound selected from: (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)propan-1-one; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-3-hydroxy-N-(oxetan-3-yl)propanamide; 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)acetamide; (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide; and (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide.
19. The compound of claim 18, wherein said compound is (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-1-(3-hydroxyazetidin-1-yl)propan-1-one.
20. The compound of claim 18, wherein said compound is 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-3-hydroxy-N-(oxetan-3-yl)propanamide.
21. The compound of claim 18, wherein said compound is 2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)acetamide.
22. The compound of claim 18, wherein said compound is (S)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide. 291499/
23. The compound of claim 18, wherein said compound is (R)-2-(2-((((1,4-trans)-4-((8-chloro-1,7-naphthyridin-2-yl)amino)cyclohexyl)methyl)amino)pyrimidin-5-yl)-N-(oxetan-3-yl)propanamide.
24. A pharmaceutical composition comprising a compound of any one of claims 1-23 and a pharmaceutically acceptable carrier.
25. A pharmaceutical composition comprising a compound of any one of claims 1-23, and one or more therapeutically active agent.
26. The pharmaceutical composition of claim 25, wherein said one or more therapeutically active agent is selected from an anti-cancer agent, immunomodulator, anti-allergic agent, anti-nausea agent, pain reliever, and a cytoprotective agent.
27. The compound of any one of claims 1-23 or the pharmaceutical composition of any one of claims 24-26 for use in a method of treating a disease or condition selected from diffuse large B cell lymphoma (DLBCL), follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, rhabdomyosarcoma, Kaposi sarcoma, synovial sarcoma, osteosarcoma and Ewing’s sarcoma.
28. The compound of any one of claims 1-23 or the pharmaceutical composition of any one of claims 24-26 for use as a medicament for treating a disease or condition selected from diffuse large B cell lymphoma (DLBCL), follicular lymphoma, leukemia, multiple myeloma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, 291499/ parathyroid tumors, uterine tumors, rhabdomyosarcoma, Kaposi sarcoma, synovial sarcoma, osteosarcoma and Ewing’s sarcoma.
29. The compound or the pharmaceutical composition for use of claim 28, wherein the medicament comprises a second therapeutic agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019108296 | 2019-09-26 | ||
| PCT/CN2020/117487 WO2021057853A1 (en) | 2019-09-26 | 2020-09-24 | Aza-quinoline compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL291499A IL291499A (en) | 2022-05-01 |
| IL291499B1 true IL291499B1 (en) | 2025-04-01 |
| IL291499B2 IL291499B2 (en) | 2025-08-01 |
Family
ID=75166744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL291499A IL291499B2 (en) | 2019-09-26 | 2020-09-24 | Azaquinoline compounds and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12544374B2 (en) |
| EP (1) | EP4034535B1 (en) |
| JP (1) | JP7763753B2 (en) |
| KR (1) | KR102889562B1 (en) |
| CN (1) | CN114746414B (en) |
| AU (1) | AU2020355837B2 (en) |
| CA (1) | CA3150284A1 (en) |
| DK (1) | DK4034535T3 (en) |
| ES (1) | ES3067468T3 (en) |
| IL (1) | IL291499B2 (en) |
| WO (1) | WO2021057853A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4034535T3 (en) | 2019-09-26 | 2026-04-07 | Novartis Ag | AZA-QUINOLINE COMPOUNDS AND THEIR USES |
| AR123185A1 (en) * | 2020-08-10 | 2022-11-09 | Novartis Ag | COMPOUNDS AND COMPOSITIONS TO INHIBIT EZH2 |
| AR128015A1 (en) * | 2021-12-16 | 2024-03-20 | Transthera Sciences Nanjing Inc | CDK9 INHIBITOR AND USE THEREOF |
| CN117384153A (en) * | 2022-07-12 | 2024-01-12 | 上海赛岚生物科技有限公司 | A class of methyltransferase inhibitors and their uses |
| CN118515653B (en) * | 2024-07-23 | 2024-12-10 | 西湖制药(杭州)有限公司 | A kind of EZH2 specific inhibitor and its preparation method and use |
| CN118598873B (en) * | 2024-08-07 | 2024-11-19 | 艾斯拓康生物医药(天津)有限公司 | Preparation method of chiral aza-quinoline compound |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| JP2002532415A (en) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Treatment of arthritis with MEK inhibitors |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| MX2008002114A (en) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | N-(arylamino)-sulfonamide inhibitors of mek. |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
| BRPI0816769A2 (en) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2014155301A1 (en) | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
| MX375970B (en) | 2014-12-23 | 2025-03-06 | Novartis Ag | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USES. |
| TW201708210A (en) | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產(第二)有限公司 | Enhancer of ZESTE homolog 2 inhibitors |
| JP2019524872A (en) | 2016-06-20 | 2019-09-05 | ノバルティス アーゲー | Imidazopyrimidine compounds useful for the treatment of cancer |
| US10689378B2 (en) | 2016-06-20 | 2020-06-23 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| MX2019004950A (en) | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Compositions and methods for treating ezh2-mediated cancer. |
| DK4034535T3 (en) | 2019-09-26 | 2026-04-07 | Novartis Ag | AZA-QUINOLINE COMPOUNDS AND THEIR USES |
-
2020
- 2020-09-24 DK DK20868772.3T patent/DK4034535T3/en active
- 2020-09-24 JP JP2022519331A patent/JP7763753B2/en active Active
- 2020-09-24 IL IL291499A patent/IL291499B2/en unknown
- 2020-09-24 US US17/632,990 patent/US12544374B2/en active Active
- 2020-09-24 AU AU2020355837A patent/AU2020355837B2/en active Active
- 2020-09-24 EP EP20868772.3A patent/EP4034535B1/en active Active
- 2020-09-24 WO PCT/CN2020/117487 patent/WO2021057853A1/en not_active Ceased
- 2020-09-24 ES ES20868772T patent/ES3067468T3/en active Active
- 2020-09-24 CA CA3150284A patent/CA3150284A1/en active Pending
- 2020-09-24 KR KR1020227011716A patent/KR102889562B1/en active Active
- 2020-09-24 CN CN202080067448.9A patent/CN114746414B/en active Active
-
2025
- 2025-11-21 US US19/396,743 patent/US20260076968A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114746414B (en) | 2024-10-18 |
| JP7763753B2 (en) | 2025-11-04 |
| EP4034535A1 (en) | 2022-08-03 |
| CN114746414A (en) | 2022-07-12 |
| US20260076968A1 (en) | 2026-03-19 |
| KR20220070229A (en) | 2022-05-30 |
| US12544374B2 (en) | 2026-02-10 |
| AU2020355837B2 (en) | 2025-10-02 |
| WO2021057853A1 (en) | 2021-04-01 |
| KR102889562B1 (en) | 2025-11-24 |
| AU2020355837A1 (en) | 2022-02-24 |
| IL291499B2 (en) | 2025-08-01 |
| DK4034535T3 (en) | 2026-04-07 |
| CA3150284A1 (en) | 2021-04-01 |
| US20220280509A1 (en) | 2022-09-08 |
| ES3067468T3 (en) | 2026-05-22 |
| JP2022550353A (en) | 2022-12-01 |
| EP4034535B1 (en) | 2026-03-04 |
| EP4034535A4 (en) | 2023-11-22 |
| IL291499A (en) | 2022-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291499B2 (en) | Azaquinoline compounds and their uses | |
| KR101917972B1 (en) | Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors | |
| CN115803325B (en) | EGFR inhibitor and preparation method and application thereof | |
| CN105461695B (en) | Pyrimidine or pyrrolotriazine derivatives and its production and use | |
| JP4667463B2 (en) | Cyclic diarylureas suitable as tyrosine kinase inhibitors | |
| KR101904632B1 (en) | 2,4-Disubstituted phenylene-1,5-Diamine Derivatives and Applications Thereof, and Pharmaceutical Compositions and Pharmaceutically Acceptable Compositions Prepared Therefrom | |
| KR101446742B1 (en) | N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidine-2,4-diamine derivatives or pharmaceutically acceptable salt thereof, and pharmaceutical composition for the prevention or treatment of cancer containing the same as an active ingredient | |
| JP2022520448A5 (en) | ||
| JP6954567B2 (en) | 2-Substituted Aromatic Ring-Pyrimidine Derivatives and Their Preparation and Medical Use | |
| JP2022550353A5 (en) | ||
| RU2016103938A (en) | MODULATORS OF PROTEIN-TYROZINKINASES AND METHODS OF THEIR APPLICATION | |
| CA2962914A1 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| JP2017519021A5 (en) | ||
| RU2734849C2 (en) | Aniline pyrimidine derivatives and use thereof | |
| CN111377907B (en) | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | |
| WO2008104754A1 (en) | Novel pyrimidine derivatives 698 | |
| CN105384694B (en) | Substituted aminopyrimidine derivative and preparation method and pharmaceutical application thereof | |
| EP4003983A1 (en) | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer | |
| TWI918753B (en) | Pyrimidine compounds, compositions, and medicinal applications thereof | |
| JP2023522195A (en) | Substituted pyridines for the treatment of inflammatory diseases | |
| JP2023538159A5 (en) | ||
| CN112313207B (en) | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | |
| CN114907341A (en) | Pyridopyrimidinone derivatives, and preparation method and application thereof | |
| RU2006107578A (en) | 6-ARILPYRIMIDINE USED AS ANTI-CANCER AGENT | |
| FI4225753T3 (en) | Potent and selective compounds as serotonin 1b receptor modulators |